RACURA ONCOLOGY

ASX Announcement

Racura Oncology Appoints Beyond Drug Development to Support the HARNESS-1 (RAC-020) Study of RC220 in Combination with Osimertinib in EGFRm Non-Small Cell Lung Cancer Patients

- Beyond Drug Development appointed to support the clinical development of RC220 for non-small cell lung cancer (NSCLC) patients in combination with osimertinib
- The HARNESS-1 Phase 1a/b trial will recruit NSCLC patients with active EGFR mutation in five sites in Australia
- Study will provide human safety, tolerability, pharmacokinetic, optimal dosage, and preliminary efficacy data with first patient expected to be recruited in Q1 CY2026.

---

24 December 2025 – Racura Oncology Limited ("Racura") is pleased to announce that it has appointed the Contract Research Organisation (CRO) Beyond Drug Development ("Beyond") to support the HARNESS-1 Phase 1a/b clinical trial of RC220 in combination with osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

Beyond were selected after an extensive and rigorous evaluation of Australian CROs conducted by the Racura Oncology clinical team and have been integral in obtaining ethics approval for the trial (ASX Announcement: 26 November 2025), along with managing other start-up activities. First patient is expected to be recruited to the study in Q1 CY2026 subject to governance approval.

Beyond are an Australian owned private company, founded by CRO industry experts with an average of 20 years' experience and with a focus on providing tailored, adaptable services to the biotechnology sector. The capabilities and flexible approach provided by Beyond supports the innovative approaches being used in the HARNESS-1 trial, these include the use of a circulating tumour DNA (ctDNA) biomarker, an initial accelerated trial design (single-patient cohorts), and a Bayesian Optimised Interval Design (BOIN) for RC220 dose optimisation.

Racura has engaged Beyond under a Master Service Agreement (MSA) with an estimated total contract cost of $3.05m over the course of the study. This cost is based on recruitment of up to 80 patients with additional passthrough costs for medical monitoring and regulatory support. Payments for services will be made after completion of key milestones, with the final total dependent on the number of recruited patients and other cost variables of trial execution.

Racura Oncology Chief Executive Officer & Managing Director commented: *"This agreement with Beyond Drug Development is a significant milestone for Racura in bring RC220 to the clinic with the aim of improving standard of care treatment for lung cancer patients. I welcome the opportunity for Racura to work with Beyond and I wish to thank the Racura clinical team for their hard work and dedication in reaching this agreement."*

-ENDS-

About Racura Oncology (ASX: RAC)

Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Racura's lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.

Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements please visit our Interactive Announcements page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@racuraoncology.com

Media contact:

Cherie Hartley +61 418 737 020
cherie.hartley@irdepartment.com.au